MediGene AG · LS:A40ESG
MediGene — H1 2022 Earnings Presentation
15 slides from MediGene's earnings presentation, Aug 3, 2022
Slide 1: Building next generation TCR-T cell therapies for solid cancers
Building next generation TCR-T cell therapies for solid cancers Medigene Half-Year Report 2022 3 August 2022 1
Slide 2: Forward looking statements disclaimer
Forward looking statements disclaimer All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to,
Slide 3: Investment highlights
Investment highlights ▪ Pipeline developed for multiple cancer indications ▪ Exclusive rights to novel solid cancer signature antigens from non-coding genome Focus on solid cancers regions (cancer’s “dark matter”) ▪ Tools to empower improved TCR-T immunotherapy of cancer → Persistence of function, s
Slide 4: A broad TCR pipeline for immunotherapy of cancer
A broad TCR pipeline for immunotherapy of cancer IND-enabling Discovery stage Clinical studies preclinical Neo-antigens incl. TCR-T cell empowering Tumor-specific „dark matter“ technologies cancer antigens Multiple targets + HLAs PD1-41BB iM-TCR Multiple targets + HLAs Wholly owned and partnered DC
Slide 5: Drug Product GMP production: Personalized TCR-Ts against cancer
Drug Product GMP production: Personalized TCR-Ts against cancer Thawing and Leukapheresis and re-infusion into patient 4 1 T cell isolation (potential to freeze) Patient TCR vector GMP: Expansion, freezing and quality tests 3 2 GMP: Activation of T cells and transfer of TCR TCR product/ One sample a
Slide 6: First proof-of-concept provided by Medigene's MDG1011 Phase I study
First proof-of-concept provided by Medigene‘s MDG1011 Phase I study MDG1011: PRAME:HLA-A2- specific TCR-T immunotherapy for blood cancers PRAME – well-characterized, broadly expressed cancer-testis antigen CD8-enriched TCR-T drug Study Outcomes products display multi-functionality Well tolerated wit
Slide 7: Discovery platform to potentially isolate "best-in-class" TCRs
Discovery platform to potentially isolate “best-in-class” TCRs for solid cancers Identify TCRs with highest Specificity, Sensitivity and Safety Discovery of optimal affinity TCRs ~10-20 healthy brings excellence to the development of donors TCR-T products for solid tumors Multi-thousands of sorted T
Slide 8: Empowered T cells for hostile solid tumor microenvironment
Empowered T cells for hostile solid tumor microenvironment – Co-stimulatory PD1-41BB switch receptor Inhibition Hypo-active T cell Current therapy options TCR-Ts + CI antibodies (anti-PD-(L)1) Inhibition • Systemic toxicity from CI therapy Exhaustion • Complex pathway for clinical development • Depe
Slide 9: Precision pairing mutational library for enhanced TCR surface expression and function
Precision pairing mutational library for enhanced TCR surface expression and function • Precision pairing of transgenic TCRs can increase TCR avidity by increasing cell surface expression • TCRs with tailored constant regions have reduced capacity to mispair with endogenous TCR chains • Library of t
Slide 10: Value creation is increased through multiplicity of products
Value creation is increased through multiplicity of products • Unique products made by combining different TCRs with different empowering technologies • Optimal product choice can address unmet medical needs for diverse cancer indications 10
Slide 11: Financials and Outlook
medigene Financials and Outlook
Slide 12: Financial outlook
Financial outlook H1 2022 Guidance 2022 Total revenues €25.3 m €23 - 28 m R&D expenses €3.7 m €11 - 15 m EBITDA €15.4 m €3 - 5 m Cash and cash equivalents as of 30 June 2022: ~€39.4 m No milestone payments or cash inflows included from existing or future partnerships or transactions Sufficient finan
Slide 13: Maximize value creation
Maximize value creation Goals - Clinical validation by Medigene and/or partners - Successfully approved treatments of solid cancers Value creation New and existing innovations to empower T cell-based immunotherapies TCRs against novel „dark matter“ antigens New-to-develop TCRs within partnering alli
Slide 14: Thank you — Q&A
medigene Thank you — Q&A
Slide 15: Contact
Contact Dr. Anna Niedl VP Investor Relations & Corporate Communications a.niedl@medigene.com +49 89 2000 3333 01 Medigene AG T +49 89 2000 33 0 Lochhamer Str. 11 F +49 89 2000 33 2920 82152 Planegg / Martinsried investor@medigene.com Germany www.medigene.com 15 © Medigene AG